These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Prognostic role of intraparotid lymph node metastasis in primary parotid cancer: Systematic review.
    Author: Guntinas-Lichius O, Thielker J, Robbins KT, Olsen KD, Shaha AR, Mäkitie AA, de Bree R, Vander Poorten V, Quer M, Rinaldo A, Kowalski LP, Rodrigo JP, Hamoir M, Ferlito A.
    Journal: Head Neck; 2021 Mar; 43(3):997-1008. PubMed ID: 33169420.
    Abstract:
    BACKGROUND: The prognostic importance of intraparotid lymph node metastasis (P+) in patients with primary parotid gland carcinoma is unclear. METHODS: Nineteen retrospective and noncomparative cohort studies, published between 1992 and 2020, met the inclusion criteria and included 2202 patients for this systematic review. RESULTS: The pooled prevalence of the P in adult patients in the unselected studies was 24.10% (95% confidence interval = 17.95-30.25). The number of P+ lymph nodes per patient was counted in only three studies and ranged from 1 to 11. The 5-year recurrence-free survival rate based on Kaplan-Meier analysis varied from 83% to 88% in P- patients compared to 36% to 54% in P+ patients. The average hazard ratio for tumor recurrence in patients with P+ compared to P- was 2.67 ± 0.58. CONCLUSIONS: P+ is an independent negative prognostic factor in primary parotid gland cancer and should be included into the treatment planning.
    [Abstract] [Full Text] [Related] [New Search]